Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Pricing of its Public Offering
05 sept. 2019 20h39 HE | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept. 05, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Proposed Public Offering
04 sept. 2019 16h02 HE | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept. 04, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with...
gmi 2018.png
Infant formula Market value to hit $98 billion by 2025: Global Market Insights, Inc.
17 avr. 2019 04h00 HE | Global Market Insights, Inc
Selbyville, Delaware, April 17, 2019 (GLOBE NEWSWIRE) -- Based on products, the infant formula market has been segmented into standard, follow-on, toddler and specialty. Among the aforementioned...
EVO.png
EVO Payments Announces Pricing of Offering of 5,000,000 Shares of Common Stock
03 avr. 2019 19h22 HE | EVO Payments, Inc.
ATLANTA, April 03, 2019 (GLOBE NEWSWIRE) -- EVO Payments, Inc. (NASDAQ: EVOP) (“EVO” or the “Company”) announced today the pricing of an underwritten offering of 5,000,000 shares of Class A common...
EVO.png
EVO Payments Announces Proposed Offering of 5,000,000 Shares of Common Stock
01 avr. 2019 16h15 HE | EVO Payments, Inc.
ATLANTA, April 01, 2019 (GLOBE NEWSWIRE) -- EVO Payments, Inc. (NASDAQ: EVOP) (“EVO” or the “Company”) announced today a proposed underwritten offering of 5,000,000 shares of its Class A common...
arotech.jpg
Arotech’s FAAC Incorporated Receives $41.1 M Follow-On Contract for U.S. Army’s Virtual Clearance Training Suite
03 avr. 2017 08h13 HE | Arotech Corporation
ANN ARBOR, Mich., April 03, 2017 (GLOBE NEWSWIRE) -- FAAC Incorporated, a part of Arotech Corporation’s Training and Simulation Division (Nasdaq:ARTX), announced that it has received a sole source...
TuftsCSDD-Logo-Color.jpg
The U.S. Remains Preferred Market for Launching New Products, According to Tufts Center for the Study of Drug Development
12 nov. 2008 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - November 12, 2008) - While the number of annual new drug approvals in the United States has declined during the past decade, the U.S. remains the preferred market for...
TuftsCSDD-Logo-Color.jpg
Clinical Trial Design Holds Key to Improved Drug Development Efficiency, According to Tufts Center for the Study of Drug Development
30 oct. 2008 10h10 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - October 30, 2008) - Improved protocol design, perhaps more than any other drug development stratagem, holds the key to faster and more efficient development, according to...
TuftsCSDD-Logo-Color.jpg
Fast Track Drugs Reach Market Sooner, According to Tufts Center for the Study of Drug Development
03 sept. 2008 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - September 3, 2008) - New drugs that receive fast track designation by the U.S. Food and Drug Administration (FDA) experience shorter clinical and approval times compared to...
TuftsCSDD-Logo-Color.jpg
Postmarketing Studies Are Becoming the Norm in the U.S., Europe, and Japan, According to Tufts Center for the Study of Drug Development
10 juil. 2008 09h00 HE | Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - July 10, 2008) - Post-approval study commitments, in which drug developers, as a condition of regulatory approval, agree to conduct research on newly marketed prescription...